149 related articles for article (PubMed ID: 10845279)
1. Eye problems in breast cancer patients treated with tamoxifen.
Paganini-Hill A; Clark LJ
Breast Cancer Res Treat; 2000 Mar; 60(2):167-72. PubMed ID: 10845279
[TBL] [Abstract][Full Text] [Related]
2. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen.
Paganini-Hill A; Clark LJ
Breast Cancer Res Treat; 2000 Nov; 64(2):165-76. PubMed ID: 11194452
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen and cataracts: a null association.
Bradbury BD; Lash TL; Kaye JA; Jick SS
Breast Cancer Res Treat; 2004 Sep; 87(2):189-96. PubMed ID: 15377843
[TBL] [Abstract][Full Text] [Related]
4. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.
Bergman L; Beelen ML; Gallee MP; Hollema H; Benraadt J; van Leeuwen FE
Lancet; 2000 Sep; 356(9233):881-7. PubMed ID: 11036892
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
6. Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors: a community based study.
Althuis MD; Sexton M; Langenberg P; Bush TL; Tkaczuk K; Magaziner J; Khoo L
Cancer; 2000 Aug; 89(4):800-10. PubMed ID: 10951343
[TBL] [Abstract][Full Text] [Related]
7. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
Nelson HD; Smith ME; Griffin JC; Fu R
Ann Intern Med; 2013 Apr; 158(8):604-14. PubMed ID: 23588749
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
Cuzick J; Forbes JF; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A;
J Natl Cancer Inst; 2007 Feb; 99(4):272-82. PubMed ID: 17312304
[TBL] [Abstract][Full Text] [Related]
9. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).
Mignotte H; Lasset C; Bonadona V; Lesur A; Luporsi E; Rodier JF; Cutuli B; Lasry S; Mauriac L; Granon C; Kerr C; Giard S; Hill C; de Lafontan B; de Gislain C; D'Anjou J; Fondrinier E; Lefeuvre C; Parache RM; Chauvin F
Int J Cancer; 1998 May; 76(3):325-30. PubMed ID: 9579567
[TBL] [Abstract][Full Text] [Related]
10. Long-term tamoxifen citrate use and potential ocular toxicity.
Gorin MB; Day R; Costantino JP; Fisher B; Redmond CK; Wickerham L; Gomolin JE; Margolese RG; Mathen MK; Bowman DM; Kaufman DI; Dimitrov NV; Singerman LJ; Bornstein R; Wolmark N
Am J Ophthalmol; 1998 Apr; 125(4):493-501. PubMed ID: 9559735
[TBL] [Abstract][Full Text] [Related]
11. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen therapy for breast cancer and endometrial cancer risk.
Bernstein L; Deapen D; Cerhan JR; Schwartz SM; Liff J; McGann-Maloney E; Perlman JA; Ford L
J Natl Cancer Inst; 1999 Oct; 91(19):1654-62. PubMed ID: 10511593
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen and ocular toxicity.
Ah-Song R; Sasco AJ
Cancer Detect Prev; 1997; 21(6):522-31. PubMed ID: 9398992
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
Swerdlow AJ; Jones ME;
J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
[TBL] [Abstract][Full Text] [Related]
15. Risk of skin cancer following tamoxifen treatment in more than 16,000 breast cancer patients: a cohort study.
Praestegaard C; Kjaer SK; Andersson M; Steding-Jensen M; Frederiksen K; Mellemkjaer L
Breast Cancer; 2016 Nov; 23(6):908-916. PubMed ID: 26660140
[TBL] [Abstract][Full Text] [Related]
16. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
Fisher B; Dignam J; Bryant J; DeCillis A; Wickerham DL; Wolmark N; Costantino J; Redmond C; Fisher ER; Bowman DM; Deschênes L; Dimitrov NV; Margolese RG; Robidoux A; Shibata H; Terz J; Paterson AH; Feldman MI; Farrar W; Evans J; Lickley HL
J Natl Cancer Inst; 1996 Nov; 88(21):1529-42. PubMed ID: 8901851
[TBL] [Abstract][Full Text] [Related]
17. Stroke risk and tamoxifen therapy for breast cancer.
Geiger AM; Fischberg GM; Chen W; Bernstein L
J Natl Cancer Inst; 2004 Oct; 96(20):1528-36. PubMed ID: 15494603
[TBL] [Abstract][Full Text] [Related]
18. Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study.
Parkkari M; Paakkala AM; Salminen L; Holli K;
Acta Ophthalmol Scand; 2003 Oct; 81(5):495-9. PubMed ID: 14510798
[TBL] [Abstract][Full Text] [Related]
19. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group.
McDonald CC; Alexander FE; Whyte BW; Forrest AP; Stewart HJ
BMJ; 1995 Oct; 311(7011):977-80. PubMed ID: 7580638
[TBL] [Abstract][Full Text] [Related]
20. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials.
Gianni L; Panzini I; Li S; Gelber RD; Collins J; Holmberg SB; Crivellari D; Castiglione-Gertsch M; Goldhirsch A; Coates AS; Ravaioli A;
Cancer; 2006 Feb; 106(3):505-13. PubMed ID: 16369994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
